🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchEcnoglutide, mazdutide, and other emerging GLP-1 pipeline agents Page 2

Ecnoglutide, mazdutide, and other emerging GLP-1 pipeline agents

TrialTracker_MD Thu, Jun 4, 2026 at 9:47 AM 19 replies 418 viewsPage 2 of 4
anders_CPH
Senior Member
1,567
7,234
Feb 2024
Copenhagen, DK
Jun 4, 2026 at 12:29 PM#6

Adding the numbers, since they settle part of this. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.

6 9CryptoCarl, MariaRD, AussieAnna and 3 others
Reply Quote Save Share Report
MikeKY_noInsulin
Member
267
1,234
Oct 2024
Louisville, KY
Jun 4, 2026 at 1:32 PM#7

Following on from james_edin — and this may be the naive question:

How long did you give it before you decided it was working?

Last edited: Jun 4, 2026 at 4:32 PM
7 10hannah_MT, Dr.SportsMedIN, amy_econ_NJ and 4 others
Reply Quote Save Share Report
Dr.ObesityLA
VIP Member
3,567
19,876
Dec 2023
Los Angeles, CA
Jun 4, 2026 at 2:35 PM#8
anders_CPH said:
Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

There is a second half to this that has not been said yet. Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the correction. That is slower than asserting, and it is the only version that survives being wrong.

8 11tampaLisa73, KarenAZ_mom, zoe_NC and 5 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Jun 4, 2026 at 3:38 PM#9

OP back with an update, since a thread like this is useless without one.

Closing this out. What actually changed my mind was the point about waiting for a trend instead of reading a single measurement, which is embarrassing in hindsight and worth saying anyway.

9 12Dr.PulmRoch, maya_sedona, stefan_berlin and 6 others
Reply Quote Save Share Report
pete_manc_UK
Senior Member
1,234
5,678
Mar 2024
Manchester, UK
Jun 4, 2026 at 8:39 PM#10
Dr.ObesityLA said:
Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the…

Agreed, and the size of the effect matters as much as its existence. Something real and small gets treated here as though it were real and decisive.

33 8mike.trainer_LA, sarah_nash92, FitDadDave and 30 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register